Please assess the completion status of the following clinical trial:

Trial Title: Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All subjects age 18 and older who have given written informed consent~2. Undergoing cardiac surgery cardiopulmonary bypass (CBP) at Weill Cornell Medical Center~Exclusion Criteria:~1. Subjects on anticoagulation medications including:~   * Clopidogrel, ticagrelor, prasugrel with platelet function analyzer-100 assay closure time (CT) prolonged greater than 15%~  * Last doses of dabigatran, rivaroxaban, apixaban within 72 hours~  * Warfarin with international normalized ratio (INR) greater than 1.5~2. Positive pregnancy test, pregnancy or lactation~3. Thrombocytopenia: platelet count less than 100,000 u/L~4. Emergency procedures~5. Proof or suspicion of a congenital or acquired coagulation disorder (e.g. von Willebrand Factor or via severe liver disease)~6. Participation in another randomized clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- RiaSTAP Arm (Type: ACTIVE_COMPARATOR): Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
- Cryopreciptiate Arm (Type: ACTIVE_COMPARATOR): Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.

Based on this trial design, predict the completion outcome and termination type (if applicable).